Investigation of Combination Aminolaevulinic Acid-Photodynamic Therapy and Hydrogel Dressing for Chronic Cutaneous Wounds

What this Trial Is About

Researchers are studying chronic infectious wounds, focusing on how different treatments may affect wound healing. This trial compares three groups of patients with chronic wounds that have not healed after at least three months of conventional treatment. The study aims to evaluate the healing rate, overall effectiveness, patient satisfaction, adverse reactions, and recurrence of wounds using photodynamic therapy (PDT), hydrogel dressing, or their combination. Patients are randomly assigned to one of three groups. Group 1 receives hydrogel dressing changes every three days along with topical mupirocin ointment applied three times daily. Group 2 undergoes four sessions of PDT spaced ten days apart, which involves applying aminolaevulinic acid to the wound, covering it with dark plastic for three hours, then illuminating it with red LED light. Group 3 receives the same PDT treatment as Group 2 followed by hydrogel dressing changes every three days. All treatments start after thorough wound cleaning and debridement to remove dead tissue and foreign bodies. During the study, patient responses and any adverse effects are recorded. Follow-up visits occur at 2, 4, 8, and 12 weeks after treatment ends to monitor wound healing and assess patient satisfaction. Researchers measure the wound healing rate, total effectiveness, and patient satisfaction up to 12 weeks post-treatment. The trial runs from January 2023 to August 2024 and includes adults aged 18 to 70 years with chronic wounds suitable for these treatments.

Photodynamic Therapy With Hydrogel Dressing for Chronic Wounds